Review



cd8 cfluorb548  (Cytek Biosciences)


Bioz Verified Symbol Cytek Biosciences is a verified supplier
Bioz Manufacturer Symbol Cytek Biosciences manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    Cytek Biosciences cd8 cfluorb548
    Fig. 3. Split subunits are functional and active in vitro. A. Cartoon schematic of antigen independent (left) and antigen dependent (right) STAT4 assay formats. B–C. The potency of the IL-12 split subunits was assessed using the antigen independent STAT4 assay in <t>CD8+</t> T cells derived from human PBMCs alone (B), or antigen dependent with MCF7-uPAR cells (C). EC50 values are displayed in (D). Technical replicates from single chain and subunit dose-response curves were used to generate EC50 values, error bars represent means ± SD.
    Cd8 Cfluorb548, supplied by Cytek Biosciences, used in various techniques. Bioz Stars score: 94/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd8+cfluorb548/cFluor+B548+Anti-Human+CD8/pm40154091-200-52-54
    Average 94 stars, based on 3 article reviews
    cd8 cfluorb548 - by Bioz Stars, 2026-09
    94/100 stars

    Images

    1) Product Images from "Self-assembling sequentially administered tumor targeted Split IL-12p35 and p40 subunits to improve the therapeutic index of systemically delivered IL-12 therapy for cancer."

    Article Title: Self-assembling sequentially administered tumor targeted Split IL-12p35 and p40 subunits to improve the therapeutic index of systemically delivered IL-12 therapy for cancer.

    Journal: Cytokine

    doi: 10.1016/j.cyto.2025.156912

    Fig. 3. Split subunits are functional and active in vitro. A. Cartoon schematic of antigen independent (left) and antigen dependent (right) STAT4 assay formats. B–C. The potency of the IL-12 split subunits was assessed using the antigen independent STAT4 assay in CD8+ T cells derived from human PBMCs alone (B), or antigen dependent with MCF7-uPAR cells (C). EC50 values are displayed in (D). Technical replicates from single chain and subunit dose-response curves were used to generate EC50 values, error bars represent means ± SD.
    Figure Legend Snippet: Fig. 3. Split subunits are functional and active in vitro. A. Cartoon schematic of antigen independent (left) and antigen dependent (right) STAT4 assay formats. B–C. The potency of the IL-12 split subunits was assessed using the antigen independent STAT4 assay in CD8+ T cells derived from human PBMCs alone (B), or antigen dependent with MCF7-uPAR cells (C). EC50 values are displayed in (D). Technical replicates from single chain and subunit dose-response curves were used to generate EC50 values, error bars represent means ± SD.

    Techniques Used: Functional Assay, In Vitro, Derivative Assay

    Fig. 5. Split subunits assemble and form functional IL-12p70 that stimulates target biology in non-human primates. A. Schematic representation of the dosing schedule for targeted split IL-12 subunits. B. Quantitative MSD (meso scale discovery) assay specific for IL-12p70 was used to detect complexed IL-12p35/p40 subunits in serum. Drug levels are shown for both cycles as mean ± SEM for complexed IL-12p70 following sequential injection of IL-12 subunits with a 4- or 24-h interval. C-E. Flow cytometry was used to analyze cell subsets in the peripheral blood of treated NHP. C and D. Cytotoxic NK cells (CD56dim CD16+) and effector memory CD8+ T cells (CCR7−CD45RA−) respond to treatment with split IL-12 subunits demonstrated by both activation (CD69) and dose dependent proliferation (Ki-67). E. Fold change of total monocyte and lymphocyte populations in NHP peripheral blood. F. Data was analyzed with FlowJo v10.8 (BD Biosciences). F. Sera from treated NHP was assessed for cytokines and biomarkers of activation by multi-spot MSD. Neopterin, IL-18, IP-10, MIG, and IL-15 demonstrated an exposure- response relationship, with greater pharmacodynamic response observed in groups with elevated IL-12p70 exposure in Cycle 1. Cycle 2 showed a reduced cytokine/ biomarker response across all treatment groups.
    Figure Legend Snippet: Fig. 5. Split subunits assemble and form functional IL-12p70 that stimulates target biology in non-human primates. A. Schematic representation of the dosing schedule for targeted split IL-12 subunits. B. Quantitative MSD (meso scale discovery) assay specific for IL-12p70 was used to detect complexed IL-12p35/p40 subunits in serum. Drug levels are shown for both cycles as mean ± SEM for complexed IL-12p70 following sequential injection of IL-12 subunits with a 4- or 24-h interval. C-E. Flow cytometry was used to analyze cell subsets in the peripheral blood of treated NHP. C and D. Cytotoxic NK cells (CD56dim CD16+) and effector memory CD8+ T cells (CCR7−CD45RA−) respond to treatment with split IL-12 subunits demonstrated by both activation (CD69) and dose dependent proliferation (Ki-67). E. Fold change of total monocyte and lymphocyte populations in NHP peripheral blood. F. Data was analyzed with FlowJo v10.8 (BD Biosciences). F. Sera from treated NHP was assessed for cytokines and biomarkers of activation by multi-spot MSD. Neopterin, IL-18, IP-10, MIG, and IL-15 demonstrated an exposure- response relationship, with greater pharmacodynamic response observed in groups with elevated IL-12p70 exposure in Cycle 1. Cycle 2 showed a reduced cytokine/ biomarker response across all treatment groups.

    Techniques Used: Functional Assay, Injection, Flow Cytometry, Activation Assay, Biomarker Discovery

    Related Articles

    Incubation:

    Article Title: Self-assembling sequentially administered tumor targeted Split IL-12p35 and p40 subunits to improve the therapeutic index of systemically delivered IL-12 therapy for cancer.
    Article Snippet: For non-human primate immunophenotyping, collected whole blood was lysed with ACK lysing buffer to remove red blood cells (ThermoFisher #A1049201), the remaining white blood cells were stained with a fixable NIR viability dye (BioLegend #423105). .. Cells were further incubated with human Fc receptor blocking antibodies (ThermoFisher #14–9161-73), and then stained with fluorophore-conjugated antibodies for the following surface markers: CD45RA BUV395 (BD Biosciences #740315), CD16 BUV496 (BD Biosciences #612944), CD69 BUV737 (BD Biosciences #612817), CD3 BV421 (BD Biosciences #562877), CD14 Pacific Blue (BioLegend #301828), CD20 BV650 (BioLegend #302336), CD8 cFluorB548 (Cytek #R7–20097), CD56 PE (BioLegend #318306), CCR7 PE-Cy7 (BioLegend #353226). .. Cells were fixed with 1× fixation/permeabilization buffer (ThermoFisher #50–112-9060), permeabilized (ThermoFisher #50–112-9059), and then stained intracellularly with Ki-67 AlexaFluor488 (BD Biosciences #561165).

    Blocking Assay:

    Article Title: Self-assembling sequentially administered tumor targeted Split IL-12p35 and p40 subunits to improve the therapeutic index of systemically delivered IL-12 therapy for cancer.
    Article Snippet: For non-human primate immunophenotyping, collected whole blood was lysed with ACK lysing buffer to remove red blood cells (ThermoFisher #A1049201), the remaining white blood cells were stained with a fixable NIR viability dye (BioLegend #423105). .. Cells were further incubated with human Fc receptor blocking antibodies (ThermoFisher #14–9161-73), and then stained with fluorophore-conjugated antibodies for the following surface markers: CD45RA BUV395 (BD Biosciences #740315), CD16 BUV496 (BD Biosciences #612944), CD69 BUV737 (BD Biosciences #612817), CD3 BV421 (BD Biosciences #562877), CD14 Pacific Blue (BioLegend #301828), CD20 BV650 (BioLegend #302336), CD8 cFluorB548 (Cytek #R7–20097), CD56 PE (BioLegend #318306), CCR7 PE-Cy7 (BioLegend #353226). .. Cells were fixed with 1× fixation/permeabilization buffer (ThermoFisher #50–112-9060), permeabilized (ThermoFisher #50–112-9059), and then stained intracellularly with Ki-67 AlexaFluor488 (BD Biosciences #561165).

    Staining:

    Article Title: Self-assembling sequentially administered tumor targeted Split IL-12p35 and p40 subunits to improve the therapeutic index of systemically delivered IL-12 therapy for cancer.
    Article Snippet: For non-human primate immunophenotyping, collected whole blood was lysed with ACK lysing buffer to remove red blood cells (ThermoFisher #A1049201), the remaining white blood cells were stained with a fixable NIR viability dye (BioLegend #423105). .. Cells were further incubated with human Fc receptor blocking antibodies (ThermoFisher #14–9161-73), and then stained with fluorophore-conjugated antibodies for the following surface markers: CD45RA BUV395 (BD Biosciences #740315), CD16 BUV496 (BD Biosciences #612944), CD69 BUV737 (BD Biosciences #612817), CD3 BV421 (BD Biosciences #562877), CD14 Pacific Blue (BioLegend #301828), CD20 BV650 (BioLegend #302336), CD8 cFluorB548 (Cytek #R7–20097), CD56 PE (BioLegend #318306), CCR7 PE-Cy7 (BioLegend #353226). .. Cells were fixed with 1× fixation/permeabilization buffer (ThermoFisher #50–112-9060), permeabilized (ThermoFisher #50–112-9059), and then stained intracellularly with Ki-67 AlexaFluor488 (BD Biosciences #561165).



    Similar Products

    cd8 cfluorb548  (Cytek Biosciences)
    94
    Cytek Biosciences cd8 cfluorb548
    Fig. 3. Split subunits are functional and active in vitro. A. Cartoon schematic of antigen independent (left) and antigen dependent (right) STAT4 assay formats. B–C. The potency of the IL-12 split subunits was assessed using the antigen independent STAT4 assay in <t>CD8+</t> T cells derived from human PBMCs alone (B), or antigen dependent with MCF7-uPAR cells (C). EC50 values are displayed in (D). Technical replicates from single chain and subunit dose-response curves were used to generate EC50 values, error bars represent means ± SD.
    Cd8 Cfluorb548, supplied by Cytek Biosciences, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd8+cfluorb548/cFluor+B548+Anti-Human+CD8/pm40154091-200-52-54
    Average 94 stars, based on 1 article reviews
    cd8 cfluorb548 - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    Fig. 3. Split subunits are functional and active in vitro. A. Cartoon schematic of antigen independent (left) and antigen dependent (right) STAT4 assay formats. B–C. The potency of the IL-12 split subunits was assessed using the antigen independent STAT4 assay in CD8+ T cells derived from human PBMCs alone (B), or antigen dependent with MCF7-uPAR cells (C). EC50 values are displayed in (D). Technical replicates from single chain and subunit dose-response curves were used to generate EC50 values, error bars represent means ± SD.

    Journal: Cytokine

    Article Title: Self-assembling sequentially administered tumor targeted Split IL-12p35 and p40 subunits to improve the therapeutic index of systemically delivered IL-12 therapy for cancer.

    doi: 10.1016/j.cyto.2025.156912

    Figure Lengend Snippet: Fig. 3. Split subunits are functional and active in vitro. A. Cartoon schematic of antigen independent (left) and antigen dependent (right) STAT4 assay formats. B–C. The potency of the IL-12 split subunits was assessed using the antigen independent STAT4 assay in CD8+ T cells derived from human PBMCs alone (B), or antigen dependent with MCF7-uPAR cells (C). EC50 values are displayed in (D). Technical replicates from single chain and subunit dose-response curves were used to generate EC50 values, error bars represent means ± SD.

    Article Snippet: Cells were further incubated with human Fc receptor blocking antibodies (ThermoFisher #14–9161-73), and then stained with fluorophore-conjugated antibodies for the following surface markers: CD45RA BUV395 (BD Biosciences #740315), CD16 BUV496 (BD Biosciences #612944), CD69 BUV737 (BD Biosciences #612817), CD3 BV421 (BD Biosciences #562877), CD14 Pacific Blue (BioLegend #301828), CD20 BV650 (BioLegend #302336), CD8 cFluorB548 (Cytek #R7–20097), CD56 PE (BioLegend #318306), CCR7 PE-Cy7 (BioLegend #353226).

    Techniques: Functional Assay, In Vitro, Derivative Assay

    Fig. 5. Split subunits assemble and form functional IL-12p70 that stimulates target biology in non-human primates. A. Schematic representation of the dosing schedule for targeted split IL-12 subunits. B. Quantitative MSD (meso scale discovery) assay specific for IL-12p70 was used to detect complexed IL-12p35/p40 subunits in serum. Drug levels are shown for both cycles as mean ± SEM for complexed IL-12p70 following sequential injection of IL-12 subunits with a 4- or 24-h interval. C-E. Flow cytometry was used to analyze cell subsets in the peripheral blood of treated NHP. C and D. Cytotoxic NK cells (CD56dim CD16+) and effector memory CD8+ T cells (CCR7−CD45RA−) respond to treatment with split IL-12 subunits demonstrated by both activation (CD69) and dose dependent proliferation (Ki-67). E. Fold change of total monocyte and lymphocyte populations in NHP peripheral blood. F. Data was analyzed with FlowJo v10.8 (BD Biosciences). F. Sera from treated NHP was assessed for cytokines and biomarkers of activation by multi-spot MSD. Neopterin, IL-18, IP-10, MIG, and IL-15 demonstrated an exposure- response relationship, with greater pharmacodynamic response observed in groups with elevated IL-12p70 exposure in Cycle 1. Cycle 2 showed a reduced cytokine/ biomarker response across all treatment groups.

    Journal: Cytokine

    Article Title: Self-assembling sequentially administered tumor targeted Split IL-12p35 and p40 subunits to improve the therapeutic index of systemically delivered IL-12 therapy for cancer.

    doi: 10.1016/j.cyto.2025.156912

    Figure Lengend Snippet: Fig. 5. Split subunits assemble and form functional IL-12p70 that stimulates target biology in non-human primates. A. Schematic representation of the dosing schedule for targeted split IL-12 subunits. B. Quantitative MSD (meso scale discovery) assay specific for IL-12p70 was used to detect complexed IL-12p35/p40 subunits in serum. Drug levels are shown for both cycles as mean ± SEM for complexed IL-12p70 following sequential injection of IL-12 subunits with a 4- or 24-h interval. C-E. Flow cytometry was used to analyze cell subsets in the peripheral blood of treated NHP. C and D. Cytotoxic NK cells (CD56dim CD16+) and effector memory CD8+ T cells (CCR7−CD45RA−) respond to treatment with split IL-12 subunits demonstrated by both activation (CD69) and dose dependent proliferation (Ki-67). E. Fold change of total monocyte and lymphocyte populations in NHP peripheral blood. F. Data was analyzed with FlowJo v10.8 (BD Biosciences). F. Sera from treated NHP was assessed for cytokines and biomarkers of activation by multi-spot MSD. Neopterin, IL-18, IP-10, MIG, and IL-15 demonstrated an exposure- response relationship, with greater pharmacodynamic response observed in groups with elevated IL-12p70 exposure in Cycle 1. Cycle 2 showed a reduced cytokine/ biomarker response across all treatment groups.

    Article Snippet: Cells were further incubated with human Fc receptor blocking antibodies (ThermoFisher #14–9161-73), and then stained with fluorophore-conjugated antibodies for the following surface markers: CD45RA BUV395 (BD Biosciences #740315), CD16 BUV496 (BD Biosciences #612944), CD69 BUV737 (BD Biosciences #612817), CD3 BV421 (BD Biosciences #562877), CD14 Pacific Blue (BioLegend #301828), CD20 BV650 (BioLegend #302336), CD8 cFluorB548 (Cytek #R7–20097), CD56 PE (BioLegend #318306), CCR7 PE-Cy7 (BioLegend #353226).

    Techniques: Functional Assay, Injection, Flow Cytometry, Activation Assay, Biomarker Discovery